Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Mavragani CP, Kirou KA, Seshan SV, Crow MK. Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford). 2023;62(7):2534-2538.

Kim JW, McKay RR, Radke MR, Zhao S, Taplin M-, Davis NB, et al. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023;41(4):871-880.

Xu Z, Yang HS, Liu L, Meng L, Lu Y, Han L, et al. Elevated levels of renal function tests conferred increased risks of developing various pregnancy complications and adverse perinatal outcomes: insights from a population-based cohort study. Clin Chem Lab Med. 2023;61(10):1760-1769.

Sciascia S, Yazdany J, Moroni G, Becker JU, Seshan SV, Andrade D, et al. Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies. Kidney Int Rep. 2023;8(4):754-763.

Hacken ET, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, et al. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023;4(2):150-169.

Liu A, Kremyanskaya M, Mehrazin R, Si Q, Robinson BD, Cushing MM, et al. Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis. Am J Hematol. 2023;98(11):1808-1813.

Panarelli NC. Infectious Mimics of Inflammatory Bowel Disease. Mod Pathol. 2023;36(7):100210.

Fahmy LM, Schreidah CM, Lapolla BA, Magro CM, Geskin LJ. VEXAS syndrome presenting as refractory cutaneous Kikuchi disease-like inflammatory pattern responding to tofacitinib. JAAD Case Rep. 2023;38:136-140.

Daniels A, Levitan D, Chernichenko N. The Rare Presentation of Multiple Chondroid Syringomas in One Patient: A Case Report. Indian J Otolaryngol Head Neck Surg. 2023;75(2):1250-1252.

Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, et al. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Sci Transl Med. 2023;15(702):eabo3826.